title: [The real measurement of non-HDL-cholesterol: Atherogenic cholesterol].
abstract: Lowe density lipoproteins (LDL) are the causal agent of cardiovascular diseases. In practice, we identify LDL with cholesterol transported in LDL (cLDL). So, cLDL has become the major target for cardiovascular prevention. Howewer, we have progressive evidences about the role of triglycerides rich lipoproteins, particularly those very low density lipoprotein (VLDL) in promotion and progression of atherosclerosis, that leads cholesterol in VLDL and its remanents as a potential therapeutic target. This feature is particularly important and of a great magnitude, in patients with hypertiglyceridemia. We can to considere, that the non-HDL cholesterol -cLDL+cVLDL+c-remmants+Lp(a)- is the real measurement of atherogenic cholesterol. In addition, non-HDL-cholesterol do not show any variations between postprandial states. In fact, non-HDL-cholesterol should be an excellent marker of atherogenic cholesterol, and an major therapeutic target in patients with atherogenic dyslipidaemia. According with different clinical trials and with the epidemiological and mendelian studies, in patients with high cardiovascular risk, optimal level of cLDL will be under 70mg/dl, and under 100 ng/dl for non-HDL-cholesterol; and in high risk patients, 100mg/dl and 130mg/dl, respectively.
authors.affiliation: Unidad de Lípidos, Servicio de Medicina Interna, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, España. Electronic address: jesus.millan@madrid.org.
authors.forename: Jesús
authors.initials: J
authors.lastname: Millán
authors.affiliation: Servicio de Endocrinología, Hospital Universitario Dr. Peset, Universitat de València, Valencia, España.
authors.forename: Antonio
authors.initials: A
authors.lastname: Hernández-Mijares
authors.affiliation: Servicio de Endocrinología, Hospital Clínico, Valencia, España.
authors.forename: Juan F
authors.initials: JF
authors.lastname: Ascaso
authors.affiliation: Área Sanitaria de Delicias, Atención Primaria, Zaragoza, España.
authors.forename: Mariano
authors.initials: M
authors.lastname: Blasco
authors.affiliation: Servicio de Medicina Interna, Hospital San Pedro, Logroño, España.
authors.forename: Angel
authors.initials: A
authors.lastname: Brea
authors.affiliation: Centro de Salud de Bembibre, Bembibre, León, España.
authors.forename: Ángel
authors.initials: Á
authors.lastname: Díaz
authors.affiliation: Departamento de Medicina, Universidad de Málaga, Málaga, España.
authors.forename: Pedro
authors.initials: P
authors.lastname: González-Santos
authors.affiliation: Centro de Salud de Prosperidad, Atención Primaria, Madrid, España.
authors.forename: Teresa
authors.initials: T
authors.lastname: Mantilla
authors.affiliation: Unidad de Lípidos y Riesgo Vascular, Servicio de Endocrinología y Nutrición, Hospital del Mar, Universidad de Barcelona, Barcelona, España.
authors.forename: Juan
authors.initials: J
authors.lastname: Pedro-Botet
authors.affiliation: Unidad de Lípidos, Servicio de Medicina Interna, Hospital Universitario de Bellvitge, Universitat de Barcelona, CIBERobn-ISCIII Barcelona, Barcelona, España.
authors.forename: Xavier
authors.initials: X
authors.lastname: Pintó
mesh_terms: D050197:Atherosclerosis / Q000097:blood* / Q000473:pathology; D002318:Cardiovascular Diseases / Q000097:blood / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood*; D018450:Disease Progression; D050171:Dyslipidemias / Q000097:blood* / Q000150:complications; D006801:Humans; D015228:Hypertriglyceridemia / Q000097:blood / Q000150:complications; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D008078:Cholesterol, LDL; D014280:Triglycerides; D002784:Cholesterol
keywords: Atherogenic dyslipidaemia; Cardiovascular prevention; Cholesterol; Colesterol; Dislipidemia aterogénica; Prevención cardiovascular; Residual Cardiovascular Risk; Riesgo cardiovascular residual